4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview

4D Molecular Therapeutics

07/08/2026 16:49

4D Molecular Therapeutics Inc FDMT.OQ FDMT.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Emeryville California-based  company is expected to report a 20,566.7% increase in revenue to $3.1 million from $15 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for 4D Molecular Therapeutics Inc is for a loss of $1.02 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $31.00, about 193.8% above its last closing price of $10.55
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.01
-0.99
-1.01
Missed
-1.8
Dec. 31 2026
-0.76
0.43
Beat
156.4
Sep. 30 2025
-1.00
-0.98
-1.01
Missed
-3.2​
Jun. 30 2025
-0.87
-0.88
-0.98
Missed
-11.9
​​Mar. 31 2025
-0.89
-0.86
-0.86
Met
0.3
Dec. 31 2024
-0.80
-0.82
-0.90
Missed
-10​
Sep. 30 2024
-0.70
-0.70
-0.79
Missed
-12.7
Jun. 30 2024
-0.71
-0.70
-0.63
Beat
10.5
This summary was machine generated August 7 at 15:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)